☆ 4.6 Article

Abstract C144: Treatment with  -catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells.

MOLECULAR CANCER THERAPEUTICS (2012)

Get Full Text
Add to Collection

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 10, Issue Supplement 1, Pages C144-C144

Publisher

American Association for Cancer Research (AACR)
DOI: 10.1158/1535-7163.targ-11-c144

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.